Business Context and Reporting Period
Company: Palatin Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: December 31, 2008
Business Overview: Palatin is a biopharmaceutical company developing peptide and small molecule compounds targeting melanocortin and natriuretic peptide receptor systems. Key programs include PL-3994 (heart failure), PL-6983 (sexual dysfunction), and a collaboration with AstraZeneca for obesity and diabetes treatments. The company has incurred negative cash flows since inception and relies on collaboration agreements and equity financing.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2008 | Six Months Ended Dec 31, 2007 |
|---|---|---|
| Revenues (Licenses & Contracts) | $1,965,251 | $9,720,566 |
| Net Loss | $(4,699,880) | $(4,030,880) |
| Net Loss Per Share (Basic/Diluted) | $(0.05) | $(0.05) |
| Operating Cash Flow | $(6,800,295) | $(10,774,956) |
| Cash and Cash Equivalents (End of Period) | $2,953,366 | $20,405,499 |
| Total Assets | $16,843,793 | $19,124,924 |
| Total Liabilities | $14,144,548 | $12,572,760 |
| Stockholders' Equity | $2,699,245 | $6,552,164 |
Liquidity: As of December 31, 2008, the company held $2.95 million in cash, $3.38 million in available-for-sale investments, and $4.90 million in accounts receivable (primarily due from AstraZeneca). Management believes these resources, combined with expected milestone payments, are sufficient to fund operations through calendar year 2009.
Material Changes vs. Prior Period
- Revenue Decline: Revenue for the six months ended Dec 31, 2008, dropped significantly to $1.97 million from $9.72 million in the prior year. This decrease is primarily due to the termination of the collaboration with King Pharmaceuticals and the recognition of remaining deferred revenue in the prior year. Current revenue is 100% derived from AstraZeneca.
- Expense Reduction: Research and Development (R&D) expenses decreased to $6.50 million from $11.74 million, and General and Administrative (G&A) expenses fell to $2.61 million from $3.99 million. These reductions are attributed to workforce reductions initiated in September 2007 and May 2008.
- Unusual Items: The company recorded a $550,968 gain on the sale of equipment and supplies previously expensed. Additionally, an income tax benefit of $1.74 million was recognized from the sale of New Jersey net operating loss carryforwards.
- Cash Position: Cash and cash equivalents decreased by approximately $6.47 million during the period, reflecting a net decrease in cash from operations, partially offset by proceeds from the sale of equipment.
Outlook, Risks, and Management Commentary
- Listing Status Risk: On December 23, 2008, Palatin received notice from the NYSE Alternext US that it failed to meet continued listing standards due to stockholders' equity falling below $4 million and trading below $0.25 per share. The company submitted a compliance plan on January 23, 2009, and intends to seek a reverse stock split to regain compliance. Failure to comply could result in delisting.
- Liquidity Risk: The company anticipates incurring additional losses. Future operations depend on successful development, regulatory approvals, and the ability to secure additional financing. If funding is unavailable, the company may curtail operations or delay clinical trials.
- Concentration Risk: 100% of revenue for the six months ended Dec 31, 2008, came from AstraZeneca. Accounts receivable are also concentrated with this single partner.
- Outlook: Management expects to incur a significant loss for the fiscal year ending June 30, 2009. The company plans to seek additional capital through public/private equity financings or collaborative arrangements.
Investor Verification Checklist
- Delisting Status: Verify the current status of the NYSE Alternext US compliance plan and whether a reverse stock split has been approved or implemented.
- Cash Runway: Confirm if the projected cash resources ($11.3 million plus expected milestones) are sufficient to fund operations beyond calendar year 2009 without further dilution.
- AstraZeneca Dependency: Assess the terms of the amended collaboration agreement and the likelihood of receiving the $2.5 million milestone payment mentioned as due in January 2009.
- Equity Dilution: Review the impact of the potential reverse stock split and any subsequent equity offerings on existing shareholders.
- Accumulated Deficit: Note the accumulated deficit of approximately $207.3 million as of December 31, 2008, indicating a long history of losses.